Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-H014 Phase 1 in Healthy Subjects
NCT06216041Phase 1Recruiting
- Sponsor
- Changchun Intellicrown Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMM-H014 in Nonalcoholic steatohepatitis (NASH) (13 cohorts), sponsored by Changchun Intellicrown Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events at 18 days and Number of participants with abnormal laboratory tests results and abnormal physical exam findings at 11 days. Started Dec 2023; status: recruiting.
02
Drugs
IMM-H014
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06216041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216041.